Natixis’s Moderna MRNA Stock Holding History

Natixis’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,000,000	Closed	-$29.5M	–	1250
2025 Q4	$29.5M	Sell	1,000,000 -600,000	-38%	-$16.3M	0.1%	143
2025 Q3	$41.3M	Buy	1,600,000 +1,000,000	+167%	+$27.9M	0.19%	89
2025 Q2	$16.6M	Buy	+600,000	New	+$15.8M	0.07%	171

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Natixis's MRNA Position: Q1 2026 in Review

Natixis sold out of Moderna (MRNA) in Q1 2026, closing a stake of 165,763 shares — an estimated $4.89M sold.

Natixis first reported a position in MRNA in Q1 2019 and held it in 22 quarters. The position peaked at $125M in Q3 2021. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

Natixis reported no remaining Moderna position as of Q1 2026 after selling out during the quarter.
Natixis sold 165,763 Moderna shares in Q1 2026, an estimated $4.89M.
Natixis first reported a position in Moderna in Q1 2019 and held it in 22 quarters.
Natixis's Moderna position peaked at $125M in Q3 2021.
722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.